1334700-32-1 Usage
General Description
(-)-(3R,4R)-1-benzyl-4-(benzylamino)piperidin-3-ol is a chemical compound with a complex molecular structure. It is classified as a piperidine derivative and contains a benzyl group and an amino group. (-)-(3R,4R)-1-benzyl-4-(benzylamino)piperidin-3-ol has stereospecific properties, with a specific arrangement of its benzyl and piperidine components. It is a chiral molecule with a specific configuration of its asymmetric carbon atoms. The compound may have potential pharmaceutical applications, as its structure suggests potential effects on biological systems, such as the central nervous system or other physiological processes. Further research is needed to fully understand its pharmacological and biochemical properties and potential uses.
Check Digit Verification of cas no
The CAS Registry Mumber 1334700-32-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,3,4,7,0 and 0 respectively; the second part has 2 digits, 3 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1334700-32:
(9*1)+(8*3)+(7*3)+(6*4)+(5*7)+(4*0)+(3*0)+(2*3)+(1*2)=121
121 % 10 = 1
So 1334700-32-1 is a valid CAS Registry Number.
1334700-32-1Relevant articles and documents
Evolution of the process for the preparation of a selective erbb vegf receptor inhibitor
Mudryk, Boguslaw,Joshi, Amit,Ortiz, Adrian,Young, Ian S.,Sawyer, James R.,Zheng, Bin,Sugiyama, Masano,Shi, Zhongping,Müslehiddino?lu, Jale,Corbett, R. Michael,Kronenthal, David R.,Conlon, David A.
, p. 305 - 312 (2013/04/10)
An efficient synthetic route to the potent and selective ErbB VEGF receptor inhibitor, BMS-690514 (1) is described. Strategic modifications in both approach and procedure addressed several issues, which led to a safe, efficient, and economical process for the preparation of multi-kilogram quantities of 1. The convergent route involves alkylation of a suitably protected (3R,4R)-4-aminopiperidin-3-ol with the triethyl(alkyl)ammonium salt of a functionalized pyrrolotriazine 3a followed by deprotection to provide 1 as the crystalline free base. Georg Thieme Verlag Stuttgart - New York.
